Mutational impact of chemotherapy on hematopoietic cells and evolution towards therapy-related pediatric AML

Autor: EJM Bertrums, JK de Kanter, AKM Rosendahl-Huber, CM Zwaan, MM van den Heuvel-Eibrink, BF Goemans, R van Boxtel

Publikováno v: Klinische Pädiatrie.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a33096e7c3a94ca7d92e0108fcecf953
https://doi.org/10.1055/s-0042-1748690

Symptoms and Suffering at the End of Life in Children with Cancer

Autor: Rjbj Gemke, CM Zwaan, T Revesz

Publikováno v: New England Journal of Medicine, 342(26), 1997-1998. MASSACHUSETTS MEDICAL SOC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70dd616330f7e72d4a46a39cccfcda71
https://doi.org/10.1056/nejm200006293422615

Cellular drug resistance in childhood acute myeloid leukemia. A mini-review with emphasis on cell culture assays

Autor: Gj, Kaspers, Cm, Zwaan, Pieters R, Anjo JP Veerman

Publikováno v: Europe PubMed Central

Cellular drug resistance is an important limiting factor in the success of chemotherapy in childhood acute myeloid leukemia (AML). We summarize the results of the studies published sofar that have focussed on drug resistance in childhood AML, using c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::646cff3995cbc97774adf00684b73009
http://europepmc.org/abstract/med/10500817

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study.

Autor: Bhatla T; Department of Pediatrics, Children's Hospital of New Jersey, Newark Beth Israel Medical Center, Newark, NJ., Hogan LE; Department of Pediatrics, Stony Brook Children's, Stony Brook, NY., Teachey DT; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Bautista F; Department of Pediatric Hematology-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pediatric Hematology-Oncology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain., Moppett J; Paediatric Haematology, Bristol Royal Hospital for Children, Bristol, United Kingdom., Velasco Puyó P; Department of Pediatric Hematology-Oncology, Vall d'Hebron Hospital, Barcelona, Spain., Micalizzi C; Clinical Experimental Haematology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy., Rossig C; Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany., Shukla N; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Gilad G; Department of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Locatelli F; Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy., Baruchel A; Pediatric Hematology and Immunology Department, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris and Université de Paris Cité, Paris, France., Zwaan CM; Department of Pediatric Hematology-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands., Bezler NS; Division of Hematology and Oncology, Connecticut Children's, University of Connecticut School of Medicine, Hartford, CT., Rubio-San-Simón A; Department of Pediatric Hematology-Oncology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain., Taussig DC; Centre for Molecular Pathology, The Royal Marsden Hospital, Institute of Cancer Research, Sutton, United Kingdom., Raetz EA; Department of Pediatrics, New York University Langone Health, New York, NY., Mao ZJ; Department of Laboratory Medicine, University of Washington, Seattle, WA., Wood BL; Department of Laboratory Medicine, University of Washington, Seattle, WA., Alvarez Arias D; Janssen Research and Development, LLC, Spring House, PA., Krevvata M; Janssen Research and Development, LLC, Spring House, PA., Nnane I; Janssen Research and Development, LLC, Spring House, PA., Bandyopadhyay N; Janssen Research and Development, LLC, Raritan, NJ., Lopez Solano L; Janssen Research and Development, LLC, Raritan, NJ., Dennis RM; Janssen Research and Development, LLC, Raritan, NJ., Carson R; Janssen Research and Development, LLC, Spring House, PA., Vora A; Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.

Publikováno v: Blood [Blood] 2024 Nov 21; Vol. 144 (21), pp. 2237-2247.

A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia.

Autor: Koedijk JB; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands.; Department of Pediatric Oncology, Erasmus MC/Sophia Children's Hospital, 3015 GD, Rotterdam, The Netherlands., van der Werf I; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, 3521 AL, Utrecht, The Netherlands.; Sanford Stem Cell Institute, Division of Regenerative Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, USA., Penter L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Hematology, Oncology, and Cancer Immunology, Campus Virchow Klinikum, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Digital Clinician Scientist Program, Charitéplatz 1, 10117, Berlin, Germany., Vermeulen MA; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands., Barneh F; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands., Perzolli A; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands.; Department of Pediatric Oncology, Erasmus MC/Sophia Children's Hospital, 3015 GD, Rotterdam, The Netherlands., Meesters-Ensing JI; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands., Metselaar DS; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands.; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Consortium (DKTK), Im Neuenheimer Feld 280, Heidelberg, Germany., Margaritis T; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands., Fiocco M; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands.; Mathematical Institute, Leiden University, Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., de Groot-Kruseman HA; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands., Moeniralam R; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands., Bang Christensen K; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark., Porter B; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pfaff K; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Garcia JS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Rodig SJ; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Hasle H; Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark., Nierkens S; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands.; Center for Translational Immunology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands., Belderbos ME; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands., Zwaan CM; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands.; Department of Pediatric Oncology, Erasmus MC/Sophia Children's Hospital, 3015 GD, Rotterdam, The Netherlands., Heidenreich O; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands. o.t.heidenreich@prinsesmaximacentrum.nl.; University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands. o.t.heidenreich@prinsesmaximacentrum.nl.; Wolfson Childhood Cancer Research Centre, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK. o.t.heidenreich@prinsesmaximacentrum.nl.

Publikováno v: Leukemia [Leukemia] 2024 Nov; Vol. 38 (11), pp. 2332-2343. Date of Electronic Publication: 2024 Aug 26.